Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital (NKI / NKI-AVL)
Research facility
Location:
Amsterdam,
Netherlands (NL)
ISNI: 0000000106741393
ROR: https://ror.org/03xqtf034
The human cell atlas (2017)
Regev A, Teichmann SA, Lander ES, Amt I, Benoist C, Birney E, Bodenmiller B, et al.
Journal article
PHIP - a novel candidate breast cancer susceptibility locus on 6q14.1 (2017)
Jiao X, Aravidis C, Marikkannu R, Rantala J, Picelli S, Adamovic T, Liu T, et al.
Journal article
Reproductive profiles and risk of breast cancer subtypes: a multi-center case-only study (2017)
Brouckaert O, Rudolph A, Laenen A, Keeman R, Bolla MK, Wang Q, Soubry A, et al.
Journal article
Genetic modifiers of CHEK2*1100delC-associated breast cancer risk (2017)
Muranen TA, Greco D, Blomqvist C, Aittomaki K, Khan S, Hogervorst F, Verhoef S, et al.
Journal article
Gene-environment interactions involving functional variants: Results from the Breast Cancer Association Consortium (2017)
Barrdahl M, Rudolph A, Hopper JL, Southey MC, Broeks A, Fasching P, Beckmann M, et al.
Journal article
Body mass index and breast cancer survival: a Mendelian randomization analysis (2017)
Guo Q, Burgess S, Turman C, Bolla MK, Wang Q, Lush M, Abraham J, et al.
Journal article
BRCA2 Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer (2017)
Shimelis H, Mesman RLS, Von Nicolai C, Ehlen A, Guidugli L, Martin C, Calleja FMGR, et al.
Journal article
TP53-based interaction analysis identifies cis-eQTL variants for TP53BP2, FBXO28, and FAM53A that associate with survival and treatment outcome in breast cancer (2017)
Fagerholm R, Khan S, Schmidt MK, Garcia-Closas M, Heikkila P, Saarela J, Beesley J, et al.
Journal article
Description of the EuroTARGET cohort: A European collaborative project on TArgeted therapy in renal cell cancer-GEnetic- and tumor-related biomarkers for response and toxicity (2017)
Van Der Zanden LFM, Vermeulen SH, Oskarsdottir A, Maurits JSF, Diekstra MHM, Ambert V, Cambon-Thomsen A, et al.
Journal article
Health-related quality of life for everolimus versus placebo in patients with advanced, non-functional, well-differentiated gastrointestinal or lung neuroendocrine tumours (RADIANT-4): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial (2017)
Pavel ME, Singh S, Strosberg JR, Bubuteishvili-Pacaud L, Degtyarev E, Neary MP, Carnaghi C, et al.
Journal article